|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 326.30 DKK | +9.02% |
|
+0.43% | -30.04% |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | -34.28 | -28.21 | -19.93 | -13.81 | 33.97 | |||||
Return on Total Capital | -42.7 | -33.31 | -22.99 | -14.8 | 35.66 | |||||
Return On Equity % | -94.4 | -110.75 | -58.43 | -21.13 | 55.06 | |||||
Return on Common Equity | -94.4 | -110.75 | -58.43 | -21.13 | 55.06 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 59.39 | 100 | 99.07 | 87.44 | 99.99 | |||||
SG&A Margin | 217.47 | 259.18 | 62.99 | 644.47 | 5.38 | |||||
EBITDA Margin % | -350.07 | -698.78 | -161.83 | -2.01K | 75.17 | |||||
EBITA Margin % | -356.27 | -782.86 | -163.73 | -2.02K | 75.06 | |||||
EBIT Margin % | -358.96 | -782.86 | -163.73 | -2.02K | 75.06 | |||||
Income From Continuing Operations Margin % | -348.01 | -928.6 | -205.3 | -1.72K | 70.05 | |||||
Net Income Margin % | -348.01 | -1.16K | -205.3 | -1.72K | 70.05 | |||||
Net Avail. For Common Margin % | -348.01 | -928.6 | -205.3 | -1.72K | 70.05 | |||||
Normalized Net Income Margin | -217.56 | -498.09 | -100.91 | -1.13K | 46.87 | |||||
Levered Free Cash Flow Margin | -253.28 | -367.48 | -66.8 | -1.17K | 47.66 | |||||
Unlevered Free Cash Flow Margin | -252.4 | -334.03 | -62.37 | -1.16K | 47.67 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.15 | 0.06 | 0.19 | 0.01 | 0.72 | |||||
Fixed Assets Turnover | 1.35 | 0.54 | 2.17 | 0.46 | 66.61 | |||||
Receivables Turnover (Average Receivables) | 4.9 | 0.77 | 2.88 | 0.43 | 70.51 | |||||
Inventory Turnover (Average Inventory) | 1.3 | - | 0.69 | 0.85 | - | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 5.15 | 6.73 | 6.25 | 21.14 | 23.57 | |||||
Quick Ratio | 4.6 | 6.73 | 6.23 | 21.11 | 23.2 | |||||
Operating Cash Flow to Current Liabilities | -3.63 | -4.82 | -1.5 | -2.31 | 9.82 | |||||
Days Sales Outstanding (Average Receivables) | 74.55 | 472.24 | 126.7 | 850.51 | 5.18 | |||||
Days Outstanding Inventory (Average Inventory) | 281.82 | - | 526.71 | 433.05 | - | |||||
Average Days Payable Outstanding | 143 | - | 5.05K | 4.69K | - | |||||
Cash Conversion Cycle (Average Days) | 213.37 | - | -4.4K | -3.41K | - | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 84.87 | 64.23 | 7.49 | 4.55 | 2.74 | |||||
Total Debt / Total Capital | 45.91 | 39.11 | 6.96 | 4.35 | 2.66 | |||||
LT Debt/Equity | 83.26 | 62.43 | 6.44 | 4.36 | 2.58 | |||||
Long-Term Debt / Total Capital | 45.04 | 38.01 | 5.99 | 4.17 | 2.51 | |||||
Total Liabilities / Total Assets | 55.13 | 47.01 | 19.55 | 9.35 | 7.01 | |||||
EBIT / Interest Expense | -256.71 | -14.09 | -21.73 | -37.27 | 238.04 | |||||
EBITDA / Interest Expense | -246.87 | -12.32 | -20.95 | -36.6 | 238.86 | |||||
(EBITDA - Capex) / Interest Expense | -252.28 | -12.53 | -21.38 | -36.89 | 237.71 | |||||
Total Debt / EBITDA | -0.78 | -0.74 | -0.22 | -0.31 | 0.06 | |||||
Net Debt / EBITDA | 0.63 | 0.92 | 2.8 | 6.95 | -2.12 | |||||
Total Debt / (EBITDA - Capex) | -0.76 | -0.72 | -0.22 | -0.31 | 0.06 | |||||
Net Debt / (EBITDA - Capex) | 0.62 | 0.9 | 2.74 | 6.89 | -2.13 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | -17.19 | -4.2 | 229.65 | -81.71 | 14.6K | |||||
Gross Profit, 1 Yr. Growth % | -33.87 | 6.57 | 226.58 | -83.86 | 16.71K | |||||
EBITDA, 1 Yr. Growth % | 29.24 | -5.46 | -23.96 | 126.88 | -650.43 | |||||
EBITA, 1 Yr. Growth % | 29.96 | 4.08 | -31.27 | 126.12 | -645.05 | |||||
EBIT, 1 Yr. Growth % | 29.83 | 4.08 | -31.27 | 126.12 | -645.05 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | 20.24 | 27.91 | -27.12 | 53.3 | -698.34 | |||||
Net Income, 1 Yr. Growth % | 20.24 | 18.07 | -41.46 | 53.3 | -698.34 | |||||
Normalized Net Income, 1 Yr. Growth % | 19.1 | 10.03 | -33.42 | 104.65 | -710.17 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | 7.61 | 18.68 | -40.5 | 30.58 | -655.54 | |||||
Accounts Receivable, 1 Yr. Growth % | 57.1 | -24.65 | 5.83 | 97.91 | 99.85 | |||||
Inventory, 1 Yr. Growth % | 82.1 | -98.91 | 517.03 | 34.82 | - | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 3.95 | -25.27 | -9.45 | -16.42 | 20.91 | |||||
Total Assets, 1 Yr. Growth % | 17.35 | -25.53 | 28.59 | 380.08 | 67.78 | |||||
Tangible Book Value, 1 Yr. Growth % | -25.41 | -6.65 | 93.72 | 444.36 | 71.84 | |||||
Common Equity, 1 Yr. Growth % | -24.53 | -12.06 | 95.22 | 440.97 | 72.11 | |||||
Cash From Operations, 1 Yr. Growth % | 75.98 | -22.26 | -54.83 | 118.67 | -801.74 | |||||
Capital Expenditures, 1 Yr. Growth % | -11.62 | -47.09 | -4.01 | -10.57 | 231.89 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | 70.81 | -35.2 | -40.38 | 221.6 | -696.34 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | 70.93 | -40.84 | -38.8 | 240.95 | -702.65 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 166.05 | -26.41 | 77.71 | -22.35 | 418.48 | |||||
Gross Profit, 2 Yr. CAGR % | 106.07 | -26.41 | 86.56 | -27.39 | 420.89 | |||||
EBITDA, 2 Yr. CAGR % | 33.55 | 11.59 | -15.04 | 31.34 | 253.38 | |||||
EBITA, 2 Yr. CAGR % | 33.15 | 14.02 | -15.29 | 24.66 | 251.07 | |||||
EBIT, 2 Yr. CAGR % | 33.65 | 14.02 | -15.29 | 24.66 | 251.07 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 33.47 | 20.17 | -3.45 | 5.7 | 202.86 | |||||
Net Income, 2 Yr. CAGR % | 33.47 | 19.15 | -16.86 | -5.27 | 202.86 | |||||
Normalized Net Income, 2 Yr. CAGR % | 32.56 | 10.92 | -14.28 | 16.73 | 253.37 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 18.51 | 9.51 | -15.97 | -11.85 | 169.35 | |||||
Accounts Receivable, 2 Yr. CAGR % | 886.09 | 57.71 | -10.7 | 29.39 | 33.46 | |||||
Inventory, 2 Yr. CAGR % | - | -85.94 | -74.12 | 188.42 | - | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 32.92 | -11.86 | -17.74 | -13 | 0.53 | |||||
Total Assets, 2 Yr. CAGR % | 13.7 | -6.52 | -2.14 | 148.46 | 183.81 | |||||
Tangible Book Value, 2 Yr. CAGR % | -16.05 | -16.56 | 34.48 | 224.74 | 205.85 | |||||
Common Equity, 2 Yr. CAGR % | -13.59 | -18.53 | 31.03 | 224.98 | 205.14 | |||||
Cash From Operations, 2 Yr. CAGR % | 72.05 | 16.96 | -40.74 | -0.61 | 291.73 | |||||
Capital Expenditures, 2 Yr. CAGR % | 2.57 | -31.62 | -28.73 | -7.34 | 72.28 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 52.75 | 5.63 | -37.69 | 38.47 | 337.93 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 52.97 | 5.57 | -39.66 | 44.46 | 353.29 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 97.5 | 36.01 | 21.31 | -16.72 | 345.83 | |||||
Gross Profit, 3 Yr. CAGR % | 71.21 | 36.46 | 20.93 | -17.49 | 345.82 | |||||
EBITDA, 3 Yr. CAGR % | 32.33 | 8.16 | -1.67 | 17.87 | 111.76 | |||||
EBITA, 3 Yr. CAGR % | 32.66 | 11.46 | -3.59 | 17.51 | 103.85 | |||||
EBIT, 3 Yr. CAGR % | 32.99 | 11.46 | -3.59 | 17.51 | 103.85 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 20.54 | 19.1 | 1.72 | 12.64 | 88.38 | |||||
Net Income, 3 Yr. CAGR % | 20.54 | 28.13 | -5.98 | 1.95 | 75.11 | |||||
Normalized Net Income, 3 Yr. CAGR % | 29.26 | 12.66 | -6.34 | 14.57 | 102.58 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 7.84 | 7.32 | -10.64 | -2.67 | 62.82 | |||||
Accounts Receivable, 3 Yr. CAGR % | 181.49 | 435.96 | 38.07 | 8.05 | 14.64 | |||||
Inventory, 3 Yr. CAGR % | - | - | -50.4 | -55.13 | - | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 141.98 | 9.7 | -11.07 | -17.3 | -2.92 | |||||
Total Assets, 3 Yr. CAGR % | 18.91 | -1.26 | 3.97 | 66.28 | 117.98 | |||||
Tangible Book Value, 3 Yr. CAGR % | -7.83 | -13.03 | 10.49 | 114.32 | 162.66 | |||||
Common Equity, 3 Yr. CAGR % | -5.98 | -13.08 | 9.02 | 110.2 | 162.93 | |||||
Cash From Operations, 3 Yr. CAGR % | 37.97 | 32.02 | -14.82 | -8.42 | 90.67 | |||||
Capital Expenditures, 3 Yr. CAGR % | 76.32 | -17.74 | -23.43 | -23.13 | 41.77 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | -11.21 | 6.36 | -12.56 | 7.68 | 125.29 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | -11.38 | 3.25 | -11.81 | 7.47 | 132.55 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 4.85 | -5.27 | 55.27 | 8.69 | 116.89 | |||||
Gross Profit, 5 Yr. CAGR % | -2.77 | -3.17 | 57.88 | 6.02 | 116.88 | |||||
EBITDA, 5 Yr. CAGR % | 55.23 | 24.41 | 4.65 | 16.99 | 64.02 | |||||
EBITA, 5 Yr. CAGR % | 54.34 | 26.78 | 4.68 | 16.64 | 61.67 | |||||
EBIT, 5 Yr. CAGR % | 54.57 | 26.78 | 4.68 | 16.64 | 61.67 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 45.28 | 28.61 | 3.9 | 13.55 | 57.37 | |||||
Net Income, 5 Yr. CAGR % | 45.28 | 34.37 | 3.9 | 13.55 | 50.12 | |||||
Normalized Net Income, 5 Yr. CAGR % | 44.3 | 24.24 | 3.25 | 14.34 | 59.31 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 29.7 | 16.23 | -8.07 | -0.81 | 38.93 | |||||
Accounts Receivable, 5 Yr. CAGR % | 44.7 | 82.71 | 106.31 | 203.55 | 30.24 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 74.61 | 59.34 | 57.16 | -0.01 | -6.6 | |||||
Total Assets, 5 Yr. CAGR % | 24.38 | 16.38 | 9.99 | 42.82 | 55.36 | |||||
Tangible Book Value, 5 Yr. CAGR % | 25.73 | 9.65 | 7.2 | 47.31 | 66.03 | |||||
Common Equity, 5 Yr. CAGR % | 27.24 | 9.65 | 7.37 | 47.3 | 64.55 | |||||
Cash From Operations, 5 Yr. CAGR % | 96.95 | 27.58 | -1.6 | 17.85 | 56.82 | |||||
Capital Expenditures, 5 Yr. CAGR % | 53.47 | 10.14 | 22.72 | -13.73 | 5.91 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 50.55 | 23.13 | -26.38 | 18.32 | 66.57 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 45.63 | 22.61 | -27.42 | 18.23 | 69.75 |
- Stock Market
- Equities
- ZEAL Stock
- Financials Zealand Pharma A/S
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
















